Basic Information
Yellox
Regulatory Information
EMEA/H/C/001198
Authorised
May 18, 2011
March 17, 2011
12
September 15, 2022
Company Information
Ireland
3013 Lake Drive Citywest Business Campus Dublin 24, D24PPT3
BAUSCH + LOMB IRELAND LIMITED
Active Ingredients
Active Substances Detail
bromfenac sodium sesquihydrate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of postoperative ocular inflammation following cataract extraction in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Yellox. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Yellox. For practical information about using Yellox, patients should read the package leaflet or contact their doctor or pharmacist.